Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Shares Sold by GW&K Investment Management LLC

GW&K Investment Management LLC lessened its stake in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Free Report) by 16.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 194,112 shares of the company's stock after selling 38,240 shares during the quarter. GW&K Investment Management LLC owned about 0.24% of Verona Pharma PLC American Depositary Share worth $12,324,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. Wellington Management Group LLP raised its holdings in Verona Pharma PLC American Depositary Share by 61.0% during the 4th quarter. Wellington Management Group LLP now owns 3,025,241 shares of the company's stock worth $140,492,000 after buying an additional 1,146,609 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Verona Pharma PLC American Depositary Share by 37.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,833,532 shares of the company's stock valued at $85,150,000 after purchasing an additional 498,338 shares during the last quarter. RTW Investments LP acquired a new stake in shares of Verona Pharma PLC American Depositary Share in the fourth quarter valued at approximately $84,568,000. Janus Henderson Group PLC raised its holdings in shares of Verona Pharma PLC American Depositary Share by 59.9% in the fourth quarter. Janus Henderson Group PLC now owns 1,667,165 shares of the company's stock valued at $77,466,000 after purchasing an additional 624,370 shares during the last quarter. Finally, Hood River Capital Management LLC raised its holdings in shares of Verona Pharma PLC American Depositary Share by 3.6% in the fourth quarter. Hood River Capital Management LLC now owns 1,485,256 shares of the company's stock valued at $68,975,000 after purchasing an additional 51,322 shares during the last quarter. Institutional investors own 85.88% of the company's stock.

Wall Street Analyst Weigh In

VRNA has been the topic of a number of recent research reports. TD Cowen downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a report on Wednesday, July 9th. Canaccord Genuity Group downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating and set a $107.00 price objective on the stock. in a report on Wednesday, July 9th. Wells Fargo & Company downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating and lowered their price objective for the company from $138.00 to $107.00 in a report on Thursday, July 10th. Roth Capital downgraded shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 10th. Finally, Cowen downgraded shares of Verona Pharma PLC American Depositary Share from a "buy" rating to a "hold" rating in a report on Wednesday, July 9th. Eleven research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $109.00.

Verona Pharma PLC American Depositary Share Stock Up 0.3%

Shares of NASDAQ VRNA traded up $0.36 during trading on Friday, reaching $105.36. The company had a trading volume of 1,332,491 shares, compared to its average volume of 2,333,076. Verona Pharma PLC American Depositary Share has a 12-month low of $18.51 and a 12-month high of $105.34. The stock has a market cap of $8.97 billion, a PE ratio of -52.67 and a beta of 0.24. The business's 50-day moving average is $90.51 and its 200 day moving average is $71.30. The company has a quick ratio of 8.73, a current ratio of 8.86 and a debt-to-equity ratio of 1.07.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of ($0.22) by $0.49. The business had revenue of $98.65 million for the quarter, compared to analysts' expectations of $41.47 million. As a group, equities analysts forecast that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Kathleen A. Rickard sold 114,984 shares of the firm's stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $8.82, for a total value of $1,014,158.88. Following the completion of the transaction, the insider directly owned 2,546,472 shares of the company's stock, valued at approximately $22,459,883.04. This trade represents a 4.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Andrew Fisher sold 80,000 shares of Verona Pharma PLC American Depositary Share stock in a transaction on Monday, June 16th. The stock was sold at an average price of $11.53, for a total transaction of $922,400.00. Following the transaction, the general counsel directly owned 359,999 shares of the company's stock, valued at $4,150,788.47. The trade was a 18.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,965,800 shares of company stock worth $20,056,881 in the last quarter. 4.80% of the stock is currently owned by insiders.

Verona Pharma PLC American Depositary Share Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.